Page last updated: 2024-12-07
p2ca peptide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
p2Ca peptide: a self-peptide derived from the enzyme alpha-ketoglutarate dehydrogenase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 132457 |
| MeSH ID | M0233858 |
Synonyms (10)
| Synonym |
|---|
| lspfpfdl |
| l-leucine, n-(n-(n-(1-(n-(1-(n-l-leucyl-l-seryl)-l-prolyl)-l-phenylalanyl)-l-prolyl)-l-phenylalanyl)-l-alpha-aspartyl)- |
| 142606-55-1 |
| p2ca-y4 |
| leucyl-seryl-prolyl-phenylalanyl-prolyl-phenylalanyl-aspartyl-leucine |
| p2ca peptide |
| p2ca |
| HY-P0260 |
| l-leucyl-l-seryl-l-prolyl-l-phenylalanyl-l-prolyl-l-phenylalanyl-l-aspartyl-l-leucine |
| (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-4-methyl |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.89) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||